TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14575647

Group type: EXPERIMENTAL
Intervention: COX-2 inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective COX-2 inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical formulations of COX-2 inhibitors
Number of subjects: 0
Study: 10376693

Group type: EXPERIMENTAL
Intervention: Treatment of H pylori infection with 14‐day therapy using clarithromycin 500 mg orally 3 times a day and omeprazole 40 mg orally once a day
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 8898601

Group type: EXPERIMENTAL
Intervention: Intervention by psychogeriatric team
Number of subjects: 69

Group type: COMPARATOR
Intervention: Normal general practitioner care (Control)
Number of subjects: 69
Study: 2005681

Group type: EXPERIMENTAL
Intervention: In situ treatment (23 patients)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Prophylactically inserted stent (41 patients)
Number of subjects: 64
Study: 6469442

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract 600 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31425803

Group type: EXPERIMENTAL
Intervention: DATLS (double adaptive threshold level set method)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: DATLS
Number of subjects: 283
Study: 30021073

Group type: EXPERIMENTAL
Intervention: Anatomic double-bundle ACL reconstruction
Number of subjects: 120

Group type: COMPARATOR
Intervention: Anatomic single-bundle ACL reconstruction
Number of subjects: 120
Study: 27010424

Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate, high-fat (LC) diet
Number of subjects: 115

Group type: COMPARATOR
Intervention: High-carbohydrate, low-fat (HC) diet
Number of subjects: 115
Study: 24499405

Group type: EXPERIMENTAL
Intervention: Intervention to promote walking
Number of subjects: 315
Study: 22442673

Group type: EXPERIMENTAL
Intervention: Centralised and specialised outpatient intervention program
Number of subjects: 268

Group type: COMPARATOR
Intervention: Standard decentralised psychiatric treatment
Number of subjects: 268
Study: 19995098

Group type: EXPERIMENTAL
Intervention: Fenofibric acid 135 mg + moderate-dose statin (rosuvastatin 20 mg, simvastatin 40 mg, atorvastatin 40 mg)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Fenofibric acid + moderate-dose statin
Number of subjects: 310
Study: 18376348

Group type: EXPERIMENTAL
Intervention: Metoprolol (0.5-1.5 mg/kg/d)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 28
Study: 16045525

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (600 microg, followed by 400 microg)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Vaginal misoprostol (800 microg, followed by 400 microg)
Number of subjects: 340
Study: 12477581

Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg IV (Group D)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Combination of droperidol 1.25 mg IV and ondansetron 4 mg IV (Group D+O)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control Group (Droperidol alone)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control Group (Combination of droperidol and ondansetron)
Number of subjects: 64
Study: 10072695

Group type: EXPERIMENTAL
Intervention: Incentives for performance in the perception task
Number of subjects: 0

Group type: COMPARATOR
Intervention: No performance incentives (Control condition)
Number of subjects: 0
Study: 8835555

Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Number of subjects: 52

Group type: COMPARATOR
Intervention: Healthy women (control group)
Number of subjects: 52
Study: 2326302

Group type: EXPERIMENTAL
Intervention: Stable isotope dilution analysis of urinary acylglycines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stable isotope dilution analysis
Number of subjects: 0
Study: 7135113

Group type: EXPERIMENTAL
Intervention: Caffeine solution (5 mg caffeine/kg body weight) ingested 1 hour prior to running
Number of subjects: 5

Group type: COMPARATOR
Intervention: Caffeine-free drink (control group)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Both groups (caffeine and control)
Number of subjects: 5
Study: 30709370

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Preventive oral care protocol
Number of subjects: 50
Study: 27723261

Group type: EXPERIMENTAL
Intervention: Mud-bath therapy (MBT) in addition to usual treatment
Number of subjects: 103

Group type: COMPARATOR
Intervention: Usual treatment alone (Control)
Number of subjects: 103
Study: 26685568

Group type: EXPERIMENTAL
Intervention: Psychoeducational group intervention
Number of subjects: 232

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 232
Study: 23504220

Group type: EXPERIMENTAL
Intervention: Public and professional education intervention
Number of subjects: 0
Study: 21837734

Group type: EXPERIMENTAL
Intervention: Terlipressin plus albumin
Number of subjects: 99

Group type: COMPARATOR
Intervention: Albumin alone
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Reversal of hepatorenal syndrome (HRS)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Liver transplantation
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Terlipressin plus albumin or albumin alone
Number of subjects: 99
Study: 19750959

Group type: EXPERIMENTAL
Intervention: Individualized physical rehabilitation (IPR) consisting of four physical therapy sessions plus three telephone calls
Number of subjects: 50

Group type: COMPARATOR
Intervention: Group wellness intervention (GWI) consisting of seven educational sessions
Number of subjects: 50
Study: 17760283

Group type: EXPERIMENTAL
Intervention: Torso Rotation (TR)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Supine Head Nodding (HN)
Number of subjects: 25
Study: 15209831

Group type: EXPERIMENTAL
Intervention: Antidepressant treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antidepressant drugs
Number of subjects: 0
Study: 11464348

Group type: EXPERIMENTAL
Intervention: 100 mg diclofenac rectally every 8 hours (group MD)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 2 g propacetamol intravenously every 6 hours (group MP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combination of 2 g propacetamol and 100 mg diclofenac (group MDP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (group M)
Number of subjects: 80
Study: 9521955

Group type: EXPERIMENTAL
Intervention: AMOX/CLAV (40 mg/kg in 3 divided doses daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PLAC
Number of subjects: 0
Study: 8041534

Group type: EXPERIMENTAL
Intervention: Oral therapy (continuous conjugated equine estrogens at 0.625 mg/day with sequential dl-norgestrel at 0.15 mg/day for 12 days each cycle)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Transdermal therapy (patches delivering continuous 17 beta-estradiol at 0.05 mg/day with sequential norethindrone acetate at 0.25 mg/day for 14 days each cycle)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Reference group (29 healthy postmenopausal women who did not request therapy)
Number of subjects: 61
Study: 2537333

Group type: EXPERIMENTAL
Intervention: oCRH (3 micrograms/kg BW, iv) plus placebo hydrocortisone (HC)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: oCRH (3 micrograms/kg BW, iv) plus HC
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo oCRH plus HC
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo oCRH plus placebo HC
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: oCRH (3 micrograms/kg BW, iv)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: HC (variable rate iv infusion)
Number of subjects: 5
Study: 1125586

Group type: EXPERIMENTAL
Intervention: Debrisoquine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Guanethidine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cost of treatment
Number of subjects: 32
Study: 30641096

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment continued after meeting switching criteria at month 3
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment continued after meeting switching criteria at month 6
Number of subjects: 1059
Study: 28741967

Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 0

Group type: COMPARATOR
Intervention: lixisenatide
Number of subjects: 0
Study: 24969363

Group type: EXPERIMENTAL
Intervention: Psychoeducational support from an interdisciplinary team
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 42
Study: 23062021

Group type: EXPERIMENTAL
Intervention: Yoga group (50-60 minutes of yogic practices daily for 42 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched hypertensive individuals)
Number of subjects: 60
Study: 21993031

Group type: EXPERIMENTAL
Intervention: Wii Fit™ use for 3 months
Number of subjects: 21
Study: 18653546

Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (ROSI)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Comparison of MET and ROSI
Number of subjects: 26
Study: 17329467

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 15166574

Group type: EXPERIMENTAL
Intervention: Interscalene nerve block
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Number of subjects: 10

Group type: COMPARATOR
Intervention: Current duration (0.05, 0.1, 0.3, 0.5, 1.0 ms)
Number of subjects: 10
Study: 11475562

Group type: EXPERIMENTAL
Intervention: Salbutamol (Steri-Neb Salamol 2.5 mg) nebulization
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo nebulization
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Salbutamol nebulization
Number of subjects: 30
Study: 9514485

Group type: EXPERIMENTAL
Intervention: Recess/resect procedures
Number of subjects: 105

Group type: COMPARATOR
Intervention: Lateral rectus recessions
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Bilateral lateral rectus recessions for simulated divergence excess
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Distance/Near difference after surgery
Number of subjects: 105
Study: 7822585

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 58
Study: 3155282

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ritanserin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31713297

Group type: EXPERIMENTAL
Intervention: Topical tamoxifen gel
Number of subjects: 150

Group type: COMPARATOR
Intervention: Oral tamoxifen 10 mg OD
Number of subjects: 150
Study: 29957279

Group type: EXPERIMENTAL
Intervention: PCYQ (n = 139)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo (n = 143)
Number of subjects: 300
Study: 27387096

Group type: EXPERIMENTAL
Intervention: POSTCARE intervention
Number of subjects: 79

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 79
Study: 23560645

Group type: EXPERIMENTAL
Intervention: Adjunctive photodynamic therapy (PDT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Adjunctive local drug delivery (LDD) with minocycline microspheres
Number of subjects: 40
Study: 22077420

Group type: EXPERIMENTAL
Intervention: Iseganan HCl 9 mg/3 ml, administered as a swish and swallow solution, six times daily for 21-28 days.
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 225
Study: 20723873

Group type: EXPERIMENTAL
Intervention: Ligaclip
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bipolar coagulation
Number of subjects: 30
Study: 18937770

Group type: EXPERIMENTAL
Intervention: KTP laser treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: IPL treatment
Number of subjects: 10
Study: 15780536

Group type: EXPERIMENTAL
Intervention: 0.025 mg estradiol and 0.125 mg norethisterone acetate daily
Number of subjects: 266

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study: 11808971

Group type: EXPERIMENTAL
Intervention: parecoxib sodium 40 mg b.i.d. for 7 days
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: ketorolac 15 mg q.i.d. for 5 days
Number of subjects: 92

Group type: COMPARATOR
Intervention: placebo for 7 days
Number of subjects: 92
Study: 10521549

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid in the media of the basilar artery in ALS patients
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 17
Study: 7782506

Group type: EXPERIMENTAL
Intervention: Fermented milk product supplemented with Lactobacillus acidophilus strain La1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fermented milk product supplemented with Bifidobacterium bifidum strain Bb 12
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified, but implied as no intervention)
Number of subjects: 0
Study: 1947550

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6967580

Group type: EXPERIMENTAL
Intervention: Ampicillin (100 mg/kg for five days)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Rifampin (20 mg/kg for four days)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Rifampin (20 mg/kg for four days) after ampicillin treatment failure
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 26
Study: 31901707

Group type: EXPERIMENTAL
Intervention: Icon arrays
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Pie charts
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Bar graphs
Number of subjects: 393

Group type: COMPARATOR
Intervention: No visualization
Number of subjects: 393
Study: 30523732

Group type: EXPERIMENTAL
Intervention: Target Temperature Management at 33°C
Number of subjects: 722

Group type: COMPARATOR
Intervention: Target Temperature Management at 36°C
Number of subjects: 722
Study: 28855078

Group type: EXPERIMENTAL
Intervention: Guided de-escalation group (1 week prasugrel followed by 1 week clopidogrel and PFT-guided maintenance therapy)
Number of subjects: 2610

Group type: COMPARATOR
Intervention: Control group (standard treatment with prasugrel for 12 months)
Number of subjects: 2610

Group type: EXPERIMENTAL
Intervention: Guided de-escalation group
Number of subjects: 2610

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2610
Study: 25877813

Group type: EXPERIMENTAL
Intervention: carnitine‐orotate complex (824 mg, three times daily)
Number of subjects: 78

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 78
Study: 23902527

Group type: EXPERIMENTAL
Intervention: Immediate primary closure (Group B)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Wounds left open (Group A)
Number of subjects: 600
Study: 21845038

Group type: EXPERIMENTAL
Intervention: Tiotropium (D group)
Number of subjects: 12163

Group type: EXPERIMENTAL
Intervention: Tiotropium (ND group)
Number of subjects: 12163
Study: 18703188

Group type: EXPERIMENTAL
Intervention: Local application of PRP gel
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional dressings
Number of subjects: 59
Study: 17234260

Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (200 mg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (no iron sucrose)
Number of subjects: 75
Study: 16398425

Group type: EXPERIMENTAL
Intervention: Pingxiao capsule (PXC) plus endocrinotherapy (ET)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Pingxiao capsule (PXC) plus chemotherapy
Number of subjects: 142

Group type: COMPARATOR
Intervention: Endocrinotherapy (ET) alone
Number of subjects: 142

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 142
Study: 12188940

Group type: EXPERIMENTAL
Intervention: High-dose mannitol (approximately 1.4 g/kg)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Conventional dose mannitol (approximately 0.7 g/kg)
Number of subjects: 141
Study: 10214558

Group type: EXPERIMENTAL
Intervention: + (R)-thalidomide
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: - (S)-thalidomide
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Racemic thalidomide
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 7649593

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 158

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Phentolamine
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Nitroprusside
Number of subjects: 158
Study: 2750828

Group type: EXPERIMENTAL
Intervention: Burch retropubic urethropexy
Number of subjects: 289

Group type: COMPARATOR
Intervention: Pereyra procedure
Number of subjects: 289

Group type: COMPARATOR
Intervention: anterior colporrhaphy
Number of subjects: 289
Study: 345433

Group type: EXPERIMENTAL
Intervention: Heparin added to dialysis solution
Number of subjects: 9

Group type: COMPARATOR
Intervention: No heparin added to dialysis solution
Number of subjects: 9
Study: 31445052

Group type: EXPERIMENTAL
Intervention: FASTED AM
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FED AM
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FED PM
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FASTED PM
Number of subjects: 12

Group type: COMPARATOR
Intervention: FED trials
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FASTED trials
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Post-lunch appetite
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 24h post-energy intake
Number of subjects: 12
Study: 27800664

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist-provided services
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 48
Study: 27571048

Group type: EXPERIMENTAL
Intervention: CPAP treatment plus usual care
Number of subjects: 2717

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 2717
Study: 24432992

Group type: EXPERIMENTAL
Intervention: Tx-RAI group (20 subjects who underwent total thyroidectomy and (131)I ablation after recombinant human TSH stimulation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tx group (20 subjects who underwent total thyroidectomy alone)
Number of subjects: 40
Study: 22023022

Group type: EXPERIMENTAL
Intervention: Concurrent alcohol and smoking treatment
Number of subjects: 96
Study: 19852293

Group type: EXPERIMENTAL
Intervention: Guishen Zhiyang Recipe (GZR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fuyang Granule (Control)
Number of subjects: 60
Study: 17688969

Group type: EXPERIMENTAL
Intervention: docetaxel/gemcitabine combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: docetaxel monotherapy
Number of subjects: 0
Study: 15730812

Group type: EXPERIMENTAL
Intervention: Dynamic bubble trap (DBT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20

Group type: COMPARATOR
Intervention: DBT and Control group
Number of subjects: 20
Study: 11507733

Group type: EXPERIMENTAL
Intervention: Prostane (herbal formulation) at a dose of two tablets a day for 1 year
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Prostane (herbal formulation)
Number of subjects: 70
Study: 9928566

Group type: EXPERIMENTAL
Intervention: Ovarian ablation (surgery or radiation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ovarian ablation plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ovarian ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 7851270

Group type: EXPERIMENTAL
Intervention: IDDM patients
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: IDDM patients with altered urinary albumin excretion rate (AER > or = 20 micrograms/min)
Number of subjects: 23
Study: 3194047

Group type: EXPERIMENTAL
Intervention: Visual information provided
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Proprioceptive information provided
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Both visual and proprioceptive information provided
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: No information provided
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Visual conditions
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Age 7 and 11 years
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Nondominant hand used by girls
Number of subjects: 270
Study: 28627186

Group type: EXPERIMENTAL
Intervention: Enterex Diabetic® (EF)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Glucerna SR® (GF)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both formulas (GF and EF)
Number of subjects: 17
Study: 25527657

Group type: EXPERIMENTAL
Intervention: Healthy diet (whole-grain products, fatty fish, and bilberries)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Whole-grain-enriched diet (same grain products as in HD, no change in fish or berry consumption)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control diet (refined-wheat breads with restrictions on fish and berries)
Number of subjects: 106
Study: 23206691

Group type: EXPERIMENTAL
Intervention: All-arthroscopic (AA) rotator cuff repair
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mini-open (MO) rotator cuff repair
Number of subjects: 100
Study: 21532512

Group type: COMPARATOR
Intervention: Oral oxybutynin
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Ultralow-dose estradiol vaginal ring
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both groups (oxybutynin and estradiol vaginal ring)
Number of subjects: 59
Study: 18453510

Group type: EXPERIMENTAL
Intervention: Herba Artemisiae annuae (Aa) tea preparation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 19
Study: 16554313

Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Percutaneous Myocardial Laser Revascularization (PMR)
Number of subjects: 68
Study: 12648191

Group type: EXPERIMENTAL
Intervention: Low Dose (LD) remifentanil (0.13 microg kg‐1 x min‐1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High Dose (HD) remifentanil (0.39 microg kg‐1 x min‐1)
Number of subjects: 18